RxDoctor Payments Data

Gayla Cragg

Psychiatric/Mental Health · Wilmington, DENPI 1730728098

Payments from drug & device makers

$778in general payments, 2019–2025

Across 9 payments — averaging $86.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$201
  • Alkermes, Inc.$187
  • Xeris Pharmaceuticals, Inc.$122
  • Teva Pharmaceuticals USA, Inc.$100
  • Otsuka America Pharmaceutical, Inc.$72
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$62
  • plus $35 from 1 others

What the payments were for

  • Food & beverage$778100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$778 in reported general payments places this provider in the 55th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$68,540
Medicare patients
88
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Paliperidone ErPaliperidone25$17,248
ClozarilClozapine12$12,336
Lurasidone Hcl33$11,160
Depakote ErDivalproex Sodium13$9,301
Divalproex Sodium ErDivalproex Sodium66$5,681
Aripiprazole78$5,000
Chlorpromazine Hcl24$4,843
Clozapine32$4,076
Divalproex Sodium100$3,320
Duloxetine Hcl33$3,238
Atomoxetine Hcl16$3,194
Lisdexamfetamine Dimesylate11$3,137
Methylphenidate ErMethylphenidate Hcl22$3,019
Fluoxetine Hcl102$2,594
Olanzapine185$2,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Loxapine$100$39111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 177 psychiatric/mental health providers in Delaware.

Other psychiatric/mental health in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →